Zymeworks (ZYME) EBITDA (2021 - 2026)

Zymeworks' EBITDA history runs 6 years deep, the most recent figure standing at -$44.6 million for Q1 2026.

• In Q1 2026, EBITDA fell 102.12% year-over-year to -$44.6 million; the TTM figure through Mar 2026 stood at -$102.8 million (up 8.5% YoY), while the FY2025 annual figure was -$80.3 million, up 34.77% from the prior year.
• EBITDA came in at -$44.6 million for Q1 2026 at Zymeworks, down from -$41.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $309.4 million in Q4 2022 to a low of -$72.6 million in Q1 2022.
• A 5-year average of -$14.2 million and a median of -$29.2 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA soared 890.33% in 2022 and plunged 104.13% in 2023, its largest moves.
• Zymeworks' EBITDA stood at $309.4 million in 2022, then slumped by 104.13% to -$12.8 million in 2023, then slumped by 91.28% to -$24.5 million in 2024, then slumped by 68.6% to -$41.2 million in 2025, then fell by 8.27% to -$44.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$44.6 million, -$41.2 million, and -$19.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison